Group 1 - The core viewpoint of the article highlights the milestone of Shenzhen reaching 600 listed companies, showcasing the strong capital vitality of the Shenzhen market, particularly in the hard technology sector [1] - HBN, a skincare brand focusing on efficacy, has submitted its listing application to the Hong Kong Stock Exchange, representing a new addition to Shenzhen's innovative landscape [1][10] - HBN's founder, Yao Zhenan, has a background in both technology and aesthetics, which has influenced the brand's commitment to genuine efficacy in skincare [3] Group 2 - HBN has established itself as a pioneer in the A-retinol anti-aging segment, with its products ranking first in sales within the category for three consecutive years from 2022 to 2024 [4] - The brand is recognized as the youngest among the top ten domestic skincare brands in China, and it leads the market for improvement-oriented skincare products [4] - HBN's research team consists of 103 members with expertise in various fields, contributing to its innovative product development and industry-leading results [6] Group 3 - HBN is the only skincare brand in China that has undergone efficacy testing by an international authority for its entire product line, reinforcing its commitment to genuine efficacy [8] - The brand has accumulated over 4.6 million repeat customers, with average repurchase rates on platforms like Tmall and Douyin significantly exceeding industry averages [8] - Financially, HBN achieved total revenue of 2.083 billion yuan in 2024, with net profit rising to 129 million yuan, indicating a healthy growth trajectory [9] Group 4 - HBN's upcoming listing on the Hong Kong Stock Exchange marks a new development phase, leveraging its commitment to rigorous research and user trust to set a differentiated path in the beauty and broader consumer sectors [10]

Core Viewpoint - The Chinese skincare brand HBN, under Shenzhen Hujia Technology (Group) Co., Ltd., has submitted its IPO application to the Hong Kong Stock Exchange, highlighting a growth model driven by deep research and rigorous validation, transitioning from "ingredient claims" to "evidence-based support" in the industry [1] Group 1: Research-Driven Innovation - HBN was founded in 2019 with the brand philosophy of "making true efficacy a reality," adhering to a long-term development path of "slow research" [4] - As of September 30, 2025, HBN's R&D team will consist of 103 members with diverse backgrounds in dermatology, medicine, cell biology, and synthetic biology, showcasing interdisciplinary collaboration [5] - HBN ranks third among domestic brands in the number of new cosmetic ingredients registered as of September 2025, indicating innovation extending from product formulation to the source ingredient [7] Group 2: Market Position and Product Innovation - HBN has become the youngest brand among the top ten domestic skincare brands in China by retail sales in 2024, and it ranks first in the market for improvement-oriented skincare products [7] - HBN's A-retinol skincare products and α-arbutin essence have ranked first in sales within their category for three consecutive years (2022-2024), establishing a clear category advantage [7] - The company has developed a complete product line based on the scientific skincare concept of "Morning C, Evening A," expanding into subcategories like eye creams and neck creams [7] Group 3: Building User Trust and Financial Performance - HBN has established a comprehensive "full-link multi-dimensional verification system," recognized as the only skincare brand in China conducting efficacy testing through international authoritative institutions [8] - As of September 2025, HBN has accumulated over 4.6 million repeat customers, with average repurchase rates of approximately 35.4% on Tmall and 44.0% on Douyin, significantly higher than industry averages [8] - In 2024, HBN achieved total revenue of 2.083 billion yuan and a net profit of 129 million yuan, with a net profit margin increasing from 3.5% to 9.6% in the first three quarters of 2025, indicating a healthy growth model driven by product strength and trust [9] Group 4: Strategic Significance of IPO - HBN's IPO in Hong Kong marks a critical milestone in its development of a "research-driven innovation and evidence-based trust" model, providing a reference for domestic brands on achieving sustainable growth amid intense market competition [11]

Group 1: IPO Dynamics - Hunan Mingming Hen Mang Commercial Chain Co., Ltd. officially listed on the Hong Kong Stock Exchange on January 28, 2026, becoming the "first stock of snack retail" in Hong Kong with the stock code "1768" [3] - Mingming Hen Mang issued a total of 15,511,200 H-shares, raising a total of HKD 3.67 billion at an issue price of HKD 236.60 per share, with a subscription rate of 1,899.49 times for public offerings and 44.44 times for international offerings [3][4] - The company has a strong cornerstone investor lineup, including Tencent and Temasek, which subscribed for USD 45 million and USD 45 million respectively, and BlackRock for USD 35 million [4] Group 2: Company Performance - As of September 30, 2025, Mingming Hen Mang operated 19,517 stores across 28 provinces and all tiered cities in China, becoming the first company in the industry to exceed 20,000 stores [5] - The company achieved a GMV of RMB 66.1 billion in the first three quarters of 2025, a year-on-year increase of 74.5%, serving 2.1 billion consumers [5] - The founder and CEO expressed the company's vision to provide affordable snacks and create a joyful experience for consumers [6] Group 3: Aixin Yuanzhi Semiconductor - Aixin Yuanzhi Semiconductor Co., Ltd. plans to list on the Hong Kong Stock Exchange on February 10, 2026, with the stock code "0600" [7] - The company aims to raise up to HKD 2.958 billion by issuing 104,915,200 H-shares at an issue price of HKD 28.20 per share, with a cornerstone investment of USD 185 million [8][9] - Aixin Yuanzhi has become the fifth largest visual edge AI inference chip supplier globally, with a market share of 24.1% in the high-end segment [9][10] Group 4: Zhuozheng Medical - Zhuozheng Medical Holdings Limited plans to list on the Hong Kong Stock Exchange on February 6, 2026, with an IPO target of over HKD 300 million [11][12] - The company has a diverse cornerstone investor base, including notable figures from the medical and technology sectors [12] - Zhuozheng Medical's revenue from 2022 to 2024 showed a compound annual growth rate of 42.2%, with a significant increase in gross profit [13] Group 5: Robotics and Automation - Tianjin Atonmo Robot Co., Ltd. submitted its IPO application to the Hong Kong Stock Exchange on January 28, 2026, focusing on high-precision robots [14][15] - The company has maintained the highest market share in domestic parallel robots for five consecutive years, with a revenue increase of 72.5% in the first three quarters of 2025 [15][16] - Atonmo's products have been applied in over 1,000 scenarios across various industries [14] Group 6: Digital MRO Services - Shanghai Xinyi Linhe Technology Co., Ltd. aims to list on the Hong Kong Stock Exchange, focusing on digital MRO procurement services [20] - The company reported a cumulative transaction volume of approximately RMB 8.5 billion in 2023, with a significant increase in revenue [21][22] - Xinyi Linhe has established partnerships with over 3,000 MRO product manufacturers and suppliers, covering more than 220,000 retail hardware stores [20] Group 7: FA Equipment Procurement - YESMRO Holdings Limited submitted its IPO application to the Hong Kong Stock Exchange, focusing on digital transformation in FA equipment procurement [24][25] - The company has achieved over 81.3% in stock availability and 96.5% in on-time delivery rates, setting industry benchmarks [24] - YESMRO has served over 24,000 different scale automation equipment manufacturers across multiple industries [25] Group 8: Skincare Industry - Shenzhen HBN Technology (Group) Co., Ltd. aims to become the "first stock of true efficacy skincare" in China, with a focus on sustainable brand development [28] - HBN has established itself among the top ten domestic skincare brands in China, with a significant market share in the improvement skincare segment [28][29] - The company reported a revenue of RMB 2.08 billion in 2024, with a notable increase in adjusted net profit [29] Group 9: Automotive Technology - Zhejiang Konghui Automotive Technology Co., Ltd. has initiated its A-share IPO process, focusing on air suspension systems [36][37] - The company has delivered over 1 million air suspension systems and established partnerships with more than 20 mainstream automotive brands [36] - Konghui has successfully entered the supply chain of international luxury automotive brands [37]

Core Viewpoint - HBN, a skincare brand, has submitted its application for a mainboard listing on the Hong Kong Stock Exchange, aiming to become the first stock representing "true efficacy skincare" in China and to leverage international capital markets for long-term development [1] Group 1: Company Overview - HBN was founded in 2019 with a commitment to the philosophy of "true efficacy" and a belief in the long-termism of "slow research" [2] - The brand has established itself among the top ten domestic skincare brands in China and is the largest domestic brand in the improvement skincare market [2] - HBN is recognized as a pioneer in the domestic retinol anti-aging sector and was one of the first brands to propose the "morning C, evening A" skincare concept [2] Group 2: Market Position and Performance - HBN's retinol and α-arbutin products have ranked first in sales in their categories for three consecutive years (2022-2024), creating a rare series of enduring bestsellers among domestic brands [2] - The company has accumulated over 4.6 million repeat customers, with average order values steadily increasing [3] - HBN's average repurchase rates on platforms like Tmall and Douyin are 35.4% and 44.0% respectively, significantly exceeding industry averages [3] Group 3: Financial Performance - HBN has experienced steady revenue growth, with total revenue reaching 2.08 billion yuan in 2024 and 1.51 billion yuan in the first three quarters of 2025, reflecting a year-on-year growth of 10.2% [4] - Adjusted net profit increased from 90 million yuan in 2023 to 130 million yuan in 2024, and further to 150 million yuan in the first three quarters of 2025 [4] - The adjusted net profit margin improved from 4.7% in 2023 to 6.2% in 2024, and reached 9.6% in the first three quarters of 2025, indicating a transition to a sustainable growth phase [4] Group 4: Research and Development - HBN has published 50 SCI-indexed papers, ranking first among domestic skincare brands for papers published as the first author [3] - The company ranks third among domestic brands in the number of new cosmetic raw materials registered by its own research and development as of September 2025 [3] - HBN has established a rigorous efficacy verification system and is the only skincare brand in China to conduct real-world efficacy testing for its entire product line through an international authority [3] Group 5: Future Outlook - HBN aims to establish a comprehensive multi-dimensional efficacy verification system throughout the product lifecycle, expanding verification from laboratories to real-world settings [4] - The company is promoting the establishment of industry standards for cosmetic efficacy evidence assessment, which is expected to lead to more standardized and transparent efficacy claims across the industry [4] - The upcoming listing in Hong Kong is seen as a critical step for HBN to transform its systematic research capabilities into broader market influence [5]

Group 1 - The core viewpoint of the article is that HBN, a domestic skincare brand, has submitted an IPO application in Hong Kong, aiming to become the first stock in the "true efficacy skincare" segment in China [2] - HBN was founded in 2019 with a focus on efficacy-driven skincare products and has ranked among the top ten domestic skincare brands in China by retail sales as of 2024 [5] - The brand has established market recognition in core efficacy ingredients and has been a pioneer in promoting the "morning C, evening A" skincare concept, achieving leading domestic sales in its product categories for three consecutive years from 2022 to 2024 [5] Group 2 - HBN has experienced rapid growth, with projected total revenue of 2.08 billion RMB for 2024 and a 10.2% year-on-year increase in revenue for the first three quarters of 2025, reaching 1.51 billion RMB [7] - The adjusted net profit is expected to grow from 90 million RMB in 2023 to 130 million RMB in 2024, further increasing to 150 million RMB in the first three quarters of 2025, with the adjusted net profit margin rising from 4.7% in 2023 to 9.6% in the first three quarters of 2025 [7] - The Chinese dermatological skincare market is one of the fastest-growing segments, with a compound annual growth rate exceeding 16.7% from 2019 to 2024, and HBN aims to leverage international capital markets for long-term development and to unlock growth potential in the efficacy skincare sector [7]

Core Viewpoint - Shenzhen HBN Technology (Group) Co., Ltd. is set to list on the Hong Kong Stock Exchange, aiming to become the first stock representing "true efficacy skincare" in China, showcasing a model of sustainable growth driven by systematic innovation in research and development [2][12]. Group 1: Company Overview - Founded in 2019, HBN adheres to the philosophy of "true efficacy" and believes in a long-term approach to research, focusing on building a healthy and sustainable brand development path [4]. - HBN has established itself among the top ten domestic skincare brands in China and is the largest domestic brand in the improvement skincare market, according to a report by ZhiShi Consulting [5]. Group 2: Market Position and Product Leadership - HBN has achieved a leading market position, particularly in the A-retinol anti-aging category, being one of the first domestic brands to propose the "morning C, evening A" skincare concept. Its A-retinol products have ranked first in sales for three consecutive years from 2022 to 2024 [7]. - The company has published 50 papers in SCI-indexed journals, ranking first among domestic skincare brands for first-author publications, demonstrating its strong research capabilities [8]. Group 3: User Trust and Financial Performance - HBN has accumulated over 4.6 million repeat customers, with average transaction values steadily increasing. The brand's average repurchase rates on platforms like Tmall and Douyin reached approximately 35.4% and 44.0% in 2025, significantly exceeding industry averages [10]. - The company reported a total revenue of 2.08 billion yuan in 2024, with a year-on-year growth of 10.2% in the first three quarters of 2025, and adjusted net profits increased from 90 million yuan in 2023 to 150 million yuan in the first three quarters of 2025 [10]. Group 4: Industry Growth and Future Potential - The skincare market in China is experiencing structural growth, with the top ten dermatological skincare brands projected to exceed 30 billion yuan in retail sales by 2024, reflecting a compound annual growth rate of over 16.7% from 2019 to 2024, outpacing the overall industry growth rate of approximately 8.6% [13]. - HBN is establishing a comprehensive efficacy verification system that spans the entire product lifecycle, aiming to enhance the credibility of efficacy claims and promote a more standardized approach within the industry [13][14].